MedTrace Logo

Sleep, Awake & Move - Part I

NCT02723396 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2024-02-13

No results posted yet for this study

Summary

Sleep benefit (SB) is a prominent spontaneous, apparently unpredictable, transitory improvement in motor function reported by around 50% of patients affected by Parkinson's Disease (PD) after sleep and before taking their first dose of dopaminergic medications. This study aims at systematically characterizing SB in PD patients in an ecological setting and to explore the relationships between nocturnal and diurnal sleep and subjective and objective measures of motor function. A better understanding of this phenomenon is mandatory for future research on this topic.

Conditions

  • Idiopathic Parkinson Disease

Sponsors & Collaborators

  • Parkinson Schweiz

    collaborator OTHER

  • Ente Ospedaliero Cantonale, Bellinzona

    collaborator OTHER

  • Penn State University

    collaborator OTHER

  • Neurocenter of Southern Switzerland

    lead OTHER

Principal Investigators

  • Pietro Luca Ratti, MD, PhD · Neurocenter of Southern Switzerland

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-16
Primary Completion
2019-05-31
Completion
2024-02-09

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02723396 on ClinicalTrials.gov